$PDSB
PDS Biotechnology Corp

2024 Q3 Form 10-Q Financial Statement

#000114036124037067 Filed on August 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.157M
YoY Change -11.4%
% of Gross Profit
Research & Development $4.528M
YoY Change -43.44%
% of Gross Profit
Depreciation & Amortization $15.12K
YoY Change 4.93%
% of Gross Profit
Operating Expenses $8.684M
YoY Change -31.6%
Operating Profit -$8.684M
YoY Change -31.6%
Interest Expense -$512.8K
YoY Change -151.51%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$9.197M
YoY Change -28.93%
Income Tax -$869.2K
% Of Pretax Income
Net Earnings -$8.328M
YoY Change -27.8%
Net Earnings / Revenue
Basic Earnings Per Share -$0.23
Diluted Earnings Per Share -$0.23
COMMON SHARES
Basic Shares Outstanding 36.82M 36.68M
Diluted Shares Outstanding 36.69M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $57.73M
YoY Change -4.77%
Cash & Equivalents $57.70M
Short-Term Investments
Other Short-Term Assets $2.428M
YoY Change -10.94%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $60.16M
YoY Change -5.03%
LONG-TERM ASSETS
Property, Plant & Equipment $152.9K
YoY Change 6.5%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $334.5K
YoY Change -17.07%
TOTAL ASSETS
Total Short-Term Assets $60.16M
Total Long-Term Assets $334.5K
Total Assets $60.50M
YoY Change -5.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.252M
YoY Change -26.33%
Accrued Expenses $1.947M
YoY Change -42.33%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $10.48M
YoY Change 19549.33%
Total Short-Term Liabilities $15.67M
YoY Change 98.31%
LONG-TERM LIABILITIES
Long-Term Debt $13.90M
YoY Change -40.6%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $13.90M
YoY Change -40.6%
TOTAL LIABILITIES
Total Short-Term Liabilities $15.67M
Total Long-Term Liabilities $13.90M
Total Liabilities $29.58M
YoY Change -5.53%
SHAREHOLDERS EQUITY
Retained Earnings -$163.4M
YoY Change 33.14%
Common Stock $12.14K
YoY Change 19.13%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $30.92M
YoY Change
Total Liabilities & Shareholders Equity $60.50M
YoY Change -5.11%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$8.328M
YoY Change -27.8%
Depreciation, Depletion And Amortization $15.12K
YoY Change 4.93%
Cash From Operating Activities -$8.858M
YoY Change 83.99%
INVESTING ACTIVITIES
Capital Expenditures $29.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$29.00K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -13.79K
YoY Change -105.75%
NET CHANGE
Cash From Operating Activities -8.858M
Cash From Investing Activities -29.00K
Cash From Financing Activities -13.79K
Net Change In Cash -8.901M
YoY Change 94.58%
FREE CASH FLOW
Cash From Operating Activities -$8.858M
Capital Expenditures $29.00K
Free Cash Flow -$8.887M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
675209
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
750654
us-gaap Investment Income Interest
InvestmentIncomeInterest
1344104
us-gaap Investment Income Interest
InvestmentIncomeInterest
1479995
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2494558
CY2024Q2 us-gaap Assets Current
AssetsCurrent
60161476
CY2023Q4 us-gaap Assets Current
AssetsCurrent
59055075
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
152938
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
134132
CY2024Q2 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
181533
CY2023Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
200873
CY2024Q2 us-gaap Assets
Assets
60495947
CY2023Q4 us-gaap Assets
Assets
59390080
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3252490
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6982824
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1947221
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2424692
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13629977
CY2024Q2 us-gaap Secured Long Term Debt
SecuredLongTermDebt
13810194
CY2023Q4 us-gaap Secured Long Term Debt
SecuredLongTermDebt
19506183
CY2024Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
93109
CY2023Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
122973
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
12137
us-gaap Operating Expenses
OperatingExpenses
18781931
us-gaap Operating Expenses
OperatingExpenses
22118587
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-8684304
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-12696173
us-gaap Operating Income Loss
OperatingIncomeLoss
-18781931
us-gaap Operating Income Loss
OperatingIncomeLoss
-22118587
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11534895
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-11534895
us-gaap Net Income Loss
NetIncomeLoss
-18931374
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21194813
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.23
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.37
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.37
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.53
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.53
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.69
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.69
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36693561
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2080319
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-9659918
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
41010953
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2105538
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
8849
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-11534895
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
32444189
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
26130947
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1630011
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-10603477
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
37183045
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1795722
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-8327897
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
57733724
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
56560517
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2427752
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
170620641
us-gaap Use Of Estimates
UseOfEstimates
<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);"> <tr> <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(B)</td> <td style="width: auto; vertical-align: top;"> <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Use of estimates:</div> </td> </tr> </table> <div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div> <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The preparation of the Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses at the date of the condensed consolidated financial statements and during the reporting periods, and to disclose contingent assets and liabilities at the date of the condensed consolidated financial statements. Actual results could differ from those estimates. The most significant estimate relates to the fair value of securities underlying stock-based compensation.</div>
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
15674774
CY2024Q2 us-gaap Liabilities
Liabilities
29578077
CY2023Q4 us-gaap Liabilities
Liabilities
33259133
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
10921
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
194337722
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-163431989
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-144500615
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
26130947
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
60495947
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
59390080
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8004852
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11231862
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13848538
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4156606
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4691321
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7550069
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8270049
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
8684304
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
12696173
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8327897
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-8327897
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18931374
us-gaap Net Income Loss
NetIncomeLoss
-21194813
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36693561
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30802498
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30802498
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35754715
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35754715
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30616310
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
44002030
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
19494473
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
30917870
us-gaap Nature Of Operations
NatureOfOperations
<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span> <span style="font-family: 'Times New Roman';"> </span></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold;">Note 1 <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">– </span>Nature of Operations</span><span style="font-family: 'Times New Roman';"><br/> </span> </div> <div><span style="font-family: 'Times New Roman';"> </span></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal;"><span style="font-size: 10pt; font-style: normal; font-weight: bold;"> <br/> </span></div> <div><span style="font-family: 'Times New Roman';"> </span></div> <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">PDS Biotechnology Corporation, a Delaware corporation (the “Company” or “PDS Biotech”), is a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted immunotherapies designed to overcome limitations of current immunotherapy and vaccine technologies. The Company develops proprietary platforms designed to train and enable the immune system to attack and destroy disease; Versamune®, and Versamune® in combination with PDS01ADC for treatments in oncology and Infectimune® for treatments in infectious diseases.  When paired with an antigen, which is a disease-related protein that is recognizable by the immune system, Versamune® and Infectimune® have both been shown to induce, <span style="font-style: italic;">in vivo</span>, large quantities of high-quality, highly potent polyfunctional CD4 helper and CD8 killer T cells, a specific sub-type of T cell that is more effective at killing infected or target cells. PDS01ADC is a novel investigational tumor-targeting fusion protein of Interleukin 12 that enhances the proliferation, potency, infiltration and longevity of T cells in the tumor microenvironment and is therefore designed to overcome the limitations of cytokine therapy which previously has resulted in high toxicity and limited therapeutic potential.  The Company’s infectious disease candidate, Infectimune®, is of potential interest for use in universal influenza vaccines. and is designed to promote the induction of disease-specific neutralizing antibodies.  The Company’s immuno-oncology product candidates are of potential interest for use as a component of combination product candidates (for example in combination with other leading technologies such as immune checkpoint inhibitors) to provide more effective treatments across a range of advanced and/or refractory cancers. The Company is also evaluating its immunotherapies as monotherapies in early-stage disease.  The Company is developing targeted product candidates to treat several cancer tumors, including Human Papillomavirus (HPV) associated cancer in head and neck squamous cell carcinoma, melanoma, colorectal, lung, breast and prostate<span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">.<br/> </span></span></div>
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4527698
CY2024Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-512762
CY2023Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-244743
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-1018612
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-482247
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37568
dei Entity Registrant Name
EntityRegistrantName
PDS Biotechnology Corp
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-4231384
dei Entity Address Address Line1
EntityAddressAddressLine1
303A College Road East
dei Entity Address City Or Town
EntityAddressCityOrTown
Princeton
dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
08540
dei City Area Code
CityAreaCode
800
dei Local Phone Number
LocalPhoneNumber
208-3343
dei Security12b Title
Security12bTitle
Common Stock, par value $0.00033 per share
dei Trading Symbol
TradingSymbol
PDSB
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
36819810
CY2024Q2 us-gaap Secured Debt Current
SecuredDebtCurrent
10416667
CY2023Q4 us-gaap Secured Debt Current
SecuredDebtCurrent
4166667
CY2024Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
58396
CY2023Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
55794
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
30917870
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001472091
dei Document Type
DocumentType
10-Q
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00033
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00033
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36779275
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36779275
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
33094521
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
33094521
CY2024Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
1187971
CY2023Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
995397
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
2362716
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
1962242
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9197066
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-12940916
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-19800543
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-22600834
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-869169
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1406021
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-869169
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1406021
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30616310
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4588522
CY2023Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
610000
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
243743
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
531091
CY2024Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
267000
us-gaap Net Income Loss
NetIncomeLoss
-18931374
us-gaap Net Income Loss
NetIncomeLoss
-21194813
us-gaap Share Based Compensation
ShareBasedCompensation
3425733
us-gaap Share Based Compensation
ShareBasedCompensation
4185857
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
267000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
610000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
554010
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
233523
us-gaap Depreciation
Depreciation
10194
us-gaap Depreciation
Depreciation
7891
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
0
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
120514
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
19339
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
20627
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-66806
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
65728
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3730334
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3195618
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-477471
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-4937383
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
0
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-179136
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18796097
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18003030
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
28999
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-28999
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
531091
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
8849
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
27261
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
33253
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
19494473
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4832265
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
19998303
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4807861
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
1173207
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-13195169
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
56560517
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
73820160
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
57733724
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
60624991
us-gaap Interest Paid Net
InterestPaidNet
2362716
us-gaap Interest Paid Net
InterestPaidNet
1962241
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6029323
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5830631
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
57700000
CY2022Q3 pdsb Shelf Registration Statement Available For Future Sale
ShelfRegistrationStatementAvailableForFutureSale
150000000
CY2022Q3 pdsb Placement Shares Available For Future Sale
PlacementSharesAvailableForFutureSale
50000000
CY2022Q3 pdsb Placement Shares Available For Future Sale
PlacementSharesAvailableForFutureSale
50000000
CY2022Q3 pdsb Commission Percentage
CommissionPercentage
0.03
CY2023 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
2642269
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
16100000
CY2024Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
0
us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
3428681
CY2024Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
19500000
CY2023Q2 pdsb Proceeds From Sale Of Unused Net Operating Loss Carryforwards
ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards
1400000
CY2024Q2 pdsb Proceeds From Sale Of Unused Net Operating Loss Carryforwards
ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards
900000
CY2024Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
57733724
CY2023Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
56560517
CY2024Q2 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
11200
CY2024Q2 us-gaap Lessor Operating Lease Term Of Contract
LessorOperatingLeaseTermOfContract
P40M
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
700000
CY2020Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
700000
CY2020Q2 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.0915
us-gaap Operating Lease Payments
OperatingLeasePayments
0
us-gaap Operating Lease Payments
OperatingLeasePayments
179136
pdsb Finance Lease Principal And Interest Payments
FinanceLeasePrincipalAndInterestPayments
34925
pdsb Finance Lease Principal And Interest Payments
FinanceLeasePrincipalAndInterestPayments
43221
CY2024Q2 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
34925
CY2024Q2 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
69850
CY2024Q2 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
40108
CY2024Q2 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
26723
CY2024Q2 pdsb Finance Lease Liability To Be Paid Year Four And Thereafter
FinanceLeaseLiabilityToBePaidYearFourAndThereafter
1
CY2024Q2 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
171607
CY2024Q2 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
20102
CY2024Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
151505
pdsb Lessee Finance Lease Number Of Leases
LesseeFinanceLeaseNumberOfLeases
4
pdsb Finance Lease Cost
FinanceLeaseCost
251959
CY2024Q2 us-gaap Lessee Finance Lease Discount Rate
LesseeFinanceLeaseDiscountRate
0.0915
pdsb Lessee Finance Lease Monthly Rental Expense
LesseeFinanceLeaseMonthlyRentalExpense
6000
CY2023 us-gaap Property Plant And Equipment Additions
PropertyPlantAndEquipmentAdditions
151490
CY2024Q2 pdsb Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
200699
CY2023Q4 pdsb Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
0
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
556385
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
827863
CY2024Q2 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
892894
CY2023Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
1289690
CY2024Q2 us-gaap Interest Payable Current
InterestPayableCurrent
296875
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
306771
CY2024Q2 us-gaap Accrued Rent Current
AccruedRentCurrent
368
CY2023Q4 us-gaap Accrued Rent Current
AccruedRentCurrent
368
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1947221
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2424692
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.0626
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.4387
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.3707
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.4207
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0426
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0359
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0404
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0405
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y11M15D
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y29D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y21D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y29D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.86
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.09
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.71
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
10.64
us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
0
CY2024Q2 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2024Q2 pdsb Liability For Uncertain Tax Positions
LiabilityForUncertainTaxPositions
0
CY2024Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2024Q2 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-900000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1400000
CY2024Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
66000
us-gaap Operating Lease Cost
OperatingLeaseCost
132000
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
126532
us-gaap Operating Lease Cost
OperatingLeaseCost
253202
CY2022Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
381625
CY2022Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
3.6685
CY2024Q2 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P10Y
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
449329
CY2024Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
1710639
CY2024Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
1184294
us-gaap Interest Expense Debt
InterestExpenseDebt
2355053
CY2023Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
961753
us-gaap Interest Expense Debt
InterestExpenseDebt
1952272
CY2024Q2 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
283774
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
554010
CY2023Q2 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
121997
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
233523
CY2024Q2 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
46995
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
113483
CY2023Q2 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
36863
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
131769
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0001140361-24-037067-index-headers.html Edgar Link pending
0001140361-24-037067-index.html Edgar Link pending
0001140361-24-037067.txt Edgar Link pending
0001140361-24-037067-xbrl.zip Edgar Link pending
ef20030064_10q.htm Edgar Link pending
ef20030064_ex31-1.htm Edgar Link pending
ef20030064_ex31-2.htm Edgar Link pending
ef20030064_ex32-1.htm Edgar Link pending
ef20030064_ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image01.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
pdsb-20240630.xsd Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
pdsb-20240630_cal.xml Edgar Link unprocessable
pdsb-20240630_def.xml Edgar Link unprocessable
pdsb-20240630_lab.xml Edgar Link unprocessable
pdsb-20240630_pre.xml Edgar Link unprocessable
ef20030064_10q_htm.xml Edgar Link completed
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending